Введение

pharmjournal

Разработка и регистрация лекарственных средств

Drug development & registration

2305-20662658-5049

LLC «CPHA»

10.33380/2305-2066-2024-13-1-1508

pharmjournal-1720

Research Article

ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ

PRECLINICAL AND CLINICAL STUDIES

Роль доксорубицина в формировании кардиотоксичности – общепринятое утверждение. Часть I. Распространенность и механизмы формирования (обзор)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)

https://orcid.org/0009-0004-5936-827X

Андреев

Д. А.

Andreev

D. A.

123098, г. Москва, ул. Маршала Новикова, д. 23

23, Marshala Novikova str., Moscow, 123098

https://orcid.org/0000-0001-5545-135X

Балакин

Е. И.

Balakin

E. I.

123098, г. Москва, ул. Маршала Новикова, д. 23

23, Marshala Novikova str., Moscow, 123098

evgbalakin@yandex.ru

https://orcid.org/0000-0002-9241-7238

Самойлов

А. С.

Samoilov

A. S.

123098, г. Москва, ул. Маршала Новикова, д. 23

23, Marshala Novikova str., Moscow, 123098

https://orcid.org/0000-0003-3396-5813

Пустовойт

В. И.

Pustovoit

V. I.

123098, г. Москва, ул. Маршала Новикова, д. 23

23, Marshala Novikova str., Moscow, 123098

vipust@yandex.ru

Федеральное государственное бюджетное учреждение «Государственный научный центр Федеральный медицинский биофизический центр им. А. И. Бурназяна ФМБА России»State Research Center – A. I. Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

2024

19012024

131190199

2024

Андреев Д.А., Балакин Е.И., Самойлов А.С., Пустовойт В.И.

Andreev D.A., Balakin E.I., Samoilov A.S., Pustovoit V.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmjournal.ru/jour/article/view/1720

Введение

Введение. Длительное использование антрациклинов в химиотерапии рака сопровождается развитием потенциально опасной для жизни кардиотоксичности. Несмотря на продолжающиеся с середины прошлого столетия исследования, подходы к выбору терапии остаются ограниченными.

Текст

Текст. В настоящее время в качестве химиотерапии наиболее широко используется доксорубицин. Ведущим механизмом побочного действия данного препарата является образование активных форм кислорода в митохондриях с опосредованным развитием окислительного стресса, способствующего повреждению миокарда. Однако несмотря на огромное количество научных работ, посвященных различным аспектам кардиотоксичности доксорубицина, ее профилактики и лечения, данный вопрос требует подробного изучения для выработки более совершенных методов ранней диагностики и своевременной кардиопротективной терапии.

Заключение

Заключение. В текущем обзоре рассматриваются патогенетические механизмы кардиотоксичности, связанные с применением химиотерапии доксорубицином. Патогенез механизма гибели кардиомиоцитов предоставит возможность разработать новые диагностические и терапевтические подходы в клинической практике врача.

Introduction

Introduction. Long-term use of anthracyclines during cancer chemotherapy has been associated with the development of potentially life-threatening cardiotoxicity. Despite researches ongoing since the middle of the last century, approaches to the choice of therapy remain limited.

Text

Text. Doxorubicin currently is the most widely used chemotherapy. The leading side effect mechanism of the drug is the formation of reactive oxygen species in mitochondria with the mediated development of oxidative stress, which contributes to myocardial damage. However, despite the huge number of scientific papers devoted to various aspects of doxorubicin cardiotoxicity, its prevention and treatment, this issue requires detailed investigation in order to develop more advanced methods for early diagnosis and timely cardioprotective therapy.

Conclusion

Conclusion. The current review discusses the pathogenetic mechanisms of cardiotoxicity associated with the use of doxorubicin chemotherapy. The pathogenesis of the cardiomyocytes death mechanism will provide an opportunity to develop new diagnostic and therapeutic approaches in the clinical practice.

антрациклиновый химиопрепаратдоксорубицинкардиотоксичностькардиомиоцитымитохондрии

anthracycline chemotherapy drugdoxorubicincardiotoxicitycardiomyocytesmitochondria

Исследование проводилось на инициативной основе.

The study was conducted on an initiative basis.

References1

Di Marco A., Cassinelli G., Arcamone F. The discovery of daunorubicin. Cancer treatment reports. 1981;65(4):3–8.

Tan C., Tasaka H., Yu K. P., Murphy M. L., Karnofsky D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3):333–353. DOI: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k.

Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnology and Bioengineering. 1969;11(6):1101–1110. DOI: 10.1002/bit.260110607.

Chaulin A. M., Duplyakov D. V. Arrhythmogenic effects of doxorubicin. Complex Issues of Cardiovascular Diseases. 2020;9(3):69–80. DOI: 10.17802/2306-1278-2020-9-3-69-80.

Yang F., Kemp C. J., Henikoff S. Doxorubicin Enhances Nucleosome Turnover around Promoters. Current Biology. 2013;23(9):782–787. DOI: 10.1016/j.cub.2013.03.043.

Von Hoff D. D. Risk Factors for Doxorubicin-lnduced Congestive Heart Failure. Annals of Internal Medicine. 1979;91(5):710. DOI: 10.7326/0003-4819-91-5-710.

Swain S. M., Whaley F. S., Ewer M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879. DOI: 10.1002/cncr.11407.

Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni C. A., Veglia F., Civelli M., Lamantia G., Colombo N., Curigliano G., Fiorentini C., Cipolla C. M. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988. DOI: 10.1161/CIRCULATIONAHA.114.013777.

Cardinale D., Sandri M. T., Martinoni A., Borghini E., Civelli M., Lamantia G., Cinieri S., Martinelli G., Fiorentini C., Cipolla C. M. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Annals of Oncology. 2002;13(5):710–715. DOI: 10.1093/annonc/mdf170.

Thavendiranathan P., Poulin F., Lim K. D., Plana J. C., Woo A., Marwick T. H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology. 2014;63(25 Pt. A):2751–2768. DOI: 10.1016/j.jacc.2014.01.073.

Linschoten M., Teske A. J., Cramer M. J., van der Wall E., Asselbergs F. W. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk. Circulation: Genomic and Precision Medicine. 2018;11(1):e001753. DOI: 10.1161/CIRCGEN.117.001753.

Miller K. D., Nogueira L., Mariotto A. B., Rowland J. H., Yabroff K. R., Alfano C. M., Jemal A., Kramer J. L., Siegel R. L. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363–385. DOI: 10.3322/caac.21565.

Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer treatment reports. 1978;62(6):865–872.

Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Annals of Internal Medicine. 1978;88(2):168–175. DOI: 10.7326/0003-4819-88-2-168.

Ewer S. M., Ewer M. S. Cardiotoxicity profile of trastuzumab. Drug Safety. 2008;31(6):459–467. DOI: 10.2165/00002018-200831060-00002.

Ferrans V. J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer treatment reports. 1978;62(6):955–961.

Shan K., Lincoff A. M., Young J. B. Anthracycline-induced cardiotoxicity. Annals of Internal Medicine. 1996;125(1):47–58. DOI: 10.7326/0003-4819-125-1-199607010-00008.

Berry G. J., Jorden M. Pathology of radiation and anthracycline cardiotoxicity. Pediatric Blood & Cancer. 2005;44(7):630–637. DOI: 10.1002/pbc.20346.

Šimůnek T., Štěrba M., Popelová O., Adamcová M., Hrdina R., Geršl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports. 2009;61(1):154–171. DOI: 10.1016/S1734-1140(09)70018-0.

Xu X., Persson H. L., Richardson D. R. Molecular Pharmacology of the Interaction of Anthracyclines with Iron. Molecular Pharmacology. 2005;68(2):261–271. DOI: 10.1124/mol.105.013383.

Doroshow J. H., Davies K. J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. Journal of Biological Chemistry. 1986;261(7):3068–3074. DOI: 10.1016/s0021-9258(17)35747-2.

Winterbourn C. C. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicology Letters. 1995;82–83:969–974. DOI: 10.1016/0378-4274(95)03532-X.

Keizer H. G., Pinedo H. M., Schuurhuis G. J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology & Therapeutics. 1990;47(2):219–231. DOI: 10.1016/0163-7258(90)90088-j.

Myers C. E., Gianni L., Simone C. B., Klecker R., Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry. 1982;21(8):1707–1712. DOI: 10.1021/bi00537a001.

Minotti G., Recalcati S., Mordente A., Liberi G., Calafiore A. M., Mancuso C., Preziosi P., Cairo G. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. The FASEB Journal. 1998;12(7):541–552. DOI: 10.1096/fasebj.12.7.541.

Bugger H., Guzman C., Zechner C., Palmeri M., Russell K. S., Russell R. R. Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemotherapy and Pharmacology. 2011;67(6):1381–1388. DOI: 10.1007/s00280-010-1441-7.

Wu X.-Y., Luo A.-Y., Zhou Y.-R., Ren J.-H. N-acetylcysteine reduces oxidative stress, nuclear factor-κB activity and cardiomyocyte apoptosis in heart failure. Molecular Medicine Reports. 2014;10(2):615–624. DOI: 10.3892/mmr.2014.2292.

Van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C. M. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews. 2011. DOI: 10.1002/14651858.CD003917.pub4.

Jo S.-H., Kim L. S., Kim S.-A., Kim H.-S., Han S.-J., Park W. J., Choi Y. J. Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial – A Prospective Randomized Study. Korean Circulation Journal. 2013;43(3):174–181. DOI: 10.4070/kcj.2013.43.3.174.

Hasinoff B. B., Patel D., Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radical Biology and Medicine. 2003;35(11):1469–1479. DOI: 10.1016/j.freeradbiomed.2003.08.005.

Popelová O., Sterba M., Simůnek T., Mazurová Y., Guncová I., Hroch M., Adamcová M., Geršl V. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. Journal of Pharmacology and Experimental Therapeutics. 2008;326(1):259–269. DOI: 10.1124/jpet.108.137604.

Elihu N., Anandasbapathy S., Frishman W. H. Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. The Journal of Clinical Pharmacology. 1998;38(2):101–105. DOI: 10.1002/j.1552-4604.1998.tb04397.x.

Giordano F. J. Oxygen, oxidative stress, hypoxia, and heart failure. Journal of Clinical Investigation. 2005;115(3):500–508. DOI: 10.1172/JCI200524408.

Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J. M. Evidence of a complex between adriamycin derivatives and cardiolipin: Possible role in cardiotoxicity. Biochemical Pharmacology. 1980;29(21):3003–3010. DOI: 10.1016/0006-2952(80)90050-7.

Childs A. C., Phaneuf S. L., Dirks A. J., Phillips T., Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Research. 2002;62(16):4592–4598.

Ichikawa Y., Ghanefar M., Bayeva M., Wu R., Khechaduri A., Naga Prasad S. V., Mutharasan R. K., Naik T. J., Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation. 2014;124(2):617–630. DOI: 10.1172/JCI72931.

Tewey K. M., Rowe T. C., Yang L., Halligan B. D., Liu L. F. Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II. Science. 1984;226(4673):466–468. DOI: 10.1126/science.6093249.

Wang J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nature Reviews Molecular Cell Biology. 2002;3(6):430–440. DOI: 10.1038/nrm831.

Zhang S., Liu X., Bawa-Khalfe T., Lu L.-S., Lyu Y. L., Liu L. F., Yeh E. T. H. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine. 2012;18(11):1639–1642. DOI: 10.1038/nm.2919.

Vavrova A., Jansova H., Mackova E., Machacek M., Haskova P., Tichotova L., Sterba M., Simunek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PloS One. 2013;8(10):e76676. DOI: 10.1371/journal.pone.0076676.

Classen S., Olland S., Berger J. M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proceedings of the National Academy of Sciences. 2003;100(19):10629–10634. DOI: 10.1073/pnas.1832879100.

Khiati S., Dalla Rosa I., Sourbier C., Ma X., Rao V. A., Neckers L. M., Zhang H., Pommier Y. Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity. Clinical Cancer Research. 2014;20(18):4873–4881. DOI: 10.1158/1078-0432.CCR-13-3373.

Lebrecht D., Kokkori A., Ketelsen U. P., Setzer B., Walker U. A. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. The Journal of Pathology. 2005;207(4):436–444. DOI: 10.1002/path.1863.

Lebrecht D., Setzer B., Ketelsen U. P., Haberstroh J., Walker U. A. Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy. Circulation. 2003;108(19):2423–2429. DOI: 10.1161/01.CIR.0000093196.59829.DF.

Yin J., Guo J., Zhang Q., Cui L., Zhang L., Zhang T., Zhao J., Li J., Middleton A., Carmichael P. L., Peng S. Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicology in Vitro. 2018;51:1–10. DOI: 10.1016/j.tiv.2018.05.001.

Vega R. B., Horton J. L., Kelly D. P. Maintaining ancient organelles. Mitochondrial biogenesis and maturation. Circulation Research. 2015;116(11):1820–1834. DOI: 10.1161/CIRCRESAHA.116.305420.

Kruiswijk F., Labuschagne C. F., Vousden K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nature Reviews Molecular Cell Biology. 2015;16(7):393–405. DOI: 10.1038/nrm4007.

Zhuang J., Ma W., Lago C. U., Hwang P. M. Metabolic regulation of oxygen and redox homeostasis by p53: lessons from evolutionary biology? Free Radical Biology and Medicine. 2012;53(6):1279–1285. DOI: 10.1016/j.freeradbiomed.2012.07.026.

Hoshino A., Mita Y., Okawa Y., Ariyoshi M., Iwai-Kanai E., Ueyama T., Ikeda K., Ogata T., Matoba S. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nature Communications. 2013;4(1):2308. DOI: 10.1038/ncomms3308.

Dhingra R., Margulets V., Chowdhury S. R., Thliveris J., Jassal D., Fernyhough P., Dorn G. W., Kirshenbaum L. A. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proceedings of the National Academy of Sciences. 2014;111(51):E5537–E5544. DOI: 10.1073/pnas.1414665111.

Fang X., Wang H., Han D., Xie E., Yang X., Wei J., Gu S., Gao F., Zhu N., Yin X., Cheng Q., Zhang P., Dai W., Chen J., Yang F., Yang H.-T., Linkermann A., Gu W., Min J., Wang F. Ferroptosis as a target for protection against cardiomyopathy. Proceedings of the National Academy of Sciences. 2019;116(7):2672–2680. DOI: 10.1073/pnas.1821022116.

Zhu W., Soonpaa M. H., Chen H., Shen W., Payne R. M., Liechty E. A., Caldwell R. L., Shou W., Field L. J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation. 2009;119(1):99–106. DOI: 10.1161/CIRCULATIONAHA.108.799700.

Zhu W., Zhang W., Shou W., Field L. J. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovascular Research. 2014;103(1):81–89. DOI: 10.1093/cvr/cvu118.

Nithipongvanitch R., Ittarat W., Velez J. M., Zhao R., St. Clair D. K., Oberley T. D. Evidence for p53 as Guardian of the Cardiomyocyte Mitochondrial Genome Following Acute Adriamycin Treatment. Journal of Histochemistry & Cytochemistry. 2007;55(6):629–639. DOI: 10.1369/jhc.6A7146.2007.

Saleme B., Gurtu V., Zhang Y., Kinnaird A., Boukouris A. E., Gopal K., Ussher J. R., Sutendra G. Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity. Science Translational Medicine. 2019;11(478):eaau8866. DOI: 10.1126/scitranslmed.aau8866.

Sala V., Li M., Ghigo A. New avenues in cardio-oncology. Aging. 2019;11(4):1075–1076. DOI: 10.18632/aging.101817.

Sawyer D. B., Zuppinger C., Miller T. A., Eppenberger H. M., Suter T. M. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation. 2002;105(13):1551–1554. DOI: 10.1161/01.CIR.0000013839.41224.1C.

Granzier H. L., Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circulation Research. 2004;94(3):284–295. DOI: 10.1161/01.RES.0000117769.88862.F8.

Ali M. A. M., Cho W. J., Hudson B., Kassiri Z., Granzier H., Schulz R. Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury. Circulation. 2010;122(20):2039–2047. DOI: 10.1161/CIRCULATIONAHA.109.930222.

Lim C. C., Zuppinger C., Guo X., Kuster G. M., Helmes M., Eppenberger H. M., Suter T. M., Liao R., Sawyer D. B. Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes. Journal of Biological Chemistry. 2004;279(9):8290–8299. DOI: 10.1074/jbc.M308033200.

Sala V., Della Sala A., Hirsch E., Ghigo A. Signaling Pathways Underlying Anthracycline Cardiotoxicity. Antioxidants & Redox Signaling. 2020;32(15):1098–1114. DOI: 10.1089/ars.2020.8019.

Galvez A. S., Diwan A., Odley A. M., Hahn H. S., Osinska H., Melendez J. G., Robbins J., Lynch R. A., Marreez Y., Dorn G. W. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circulation Research. 2007;100(7):1071–1078. DOI: 10.1161/01.RES.0000261938.28365.11.

Taneike M., Mizote I., Morita T., Watanabe T., Hikoso S., Yamaguchi O., Takeda T. , Oka T., Tamai T., Oyabu J., Murakawa T., Nakayama H., Nishida K., Takeda J., Mochizuki N., Komuro I., Otsu K. Calpain protects the heart from hemodynamic stress. Journal of Biological Chemistry. 2011;286(37):32170–32177. DOI: 10.1074/jbc.M111.248088.

Wang Y., Zheng D., Wei M., Ma J., Yu Y., Chen R., Lacefield J. C., Xu H., Peng T. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin. Cardiovascular Research. 2013;98(3):381–390. DOI: 10.1093/cvr/cvt048.

Chan B. Y. H., Roczkowsky A., Moser N., Poirier M., Hughes B. G., Ilarraza R., Schulz R. Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes. Canadian Journal of Physiology and Pharmacology. 2018;96(12):1238–1245. DOI: 10.1139/cjpp-2018-0275.

Doucet A., Overall C. Protease proteomics: Revealing protease in vivo functions using systems biology approaches. Molecular Aspects of Medicine. 2008;29(5):339–358. DOI: 10.1016/j.mam.2008.04.003.

McCawley L. J., Matrisian L. M. Matrix metalloproteinases: they’re not just for matrix anymore! Current Opinion in Cell Biology. 2001;13(5):534–540. DOI: 10.1016/s0955-0674(00)00248-9.

Gao C. Q., Sawicki G., Suarez-Pinzon W. L., Csont T., Wozniak M., Ferdinandy P., Schulz R. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovascular Research. 2003;57(2):426–433. DOI: 10.1016/s0008-6363(02)00719-8.

Wang W., Schulze C. J., Suarez-Pinzon W. L., Dyck J. R. B., Sawicki G., Schulz R. Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury. Circulation. 2002;106(12):1543–1549. DOI: 10.1161/01.CIR.0000028818.33488.7B.

Sawicki G., Leon H., Sawicka J., Sariahmetoglu M., Schulze C. J., Scott P. G., Szczesna-Cordary D., Schulz R. Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2. Circulation. 2005;112(4):544–552. DOI: 10.1161/CIRCULATIONAHA.104.531616.

Sung M. M., Schulz C. G., Wang W., Sawicki G., Bautista-López N. L., Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein α-actinin in peroxynitrite mediated myocardial injury. Journal of Molecular and Cellular Cardiology. 2007;43(4):429–436. DOI: 10.1016/j.yjmcc.2007.07.055.

Bergman M. R., Teerlink J. R., Mahimkar R., Li L., Zhu B. Q., Nguyen A., Dahi S., Karliner J. S., Lovett D. H. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(4):H1847–H1860. DOI: 10.1152/ajpheart.00434.2006.

Chan B. Y. H., Roczkowsky A., Cho W. J., Poirier M., Sergi C., Keschrumrus V., Churko J. M., Granzier H., Schulz R. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling. Cardiovascular Research. 2021;117(1):188–200. DOI: 10.1093/cvr/cvaa017.

Tanihata J., Nishioka N., Inoue T., Bando K., Minamisawa S. Urinary Titin Is Increased in Patients After Cardiac Surgery. Frontiers in Cardiovascular Medicine. 2019;6. DOI: 10.3389/fcvm.2019.00007.

Zhang T., Zhang Y., Cui M., Jin L., Wang Y., Lv F., Liu Y., Zheng W., Shang H., Zhang J., Zhang M., Wu H., Guo J., Zhang X., Hu X., Cao C.-M., Xiao R.-P. CaMKII is a RIP3 substrate mediating ischemiaand oxidative stress-induced myocardial necroptosis. Nature Medicine. 2016;22(2):175–182. DOI: 10.1038/nm.4017.

Meng L., Lin H., Zhang J., Lin N., Sun Z., Gao F., Luo H., Ni T., Luo W., Chi J., Guo H. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. Journal of Molecular and Cellular Cardiology. 2019;136:15–26. DOI: 10.1016/j.yjmcc.2019.08.009.

Zheng X., Zhong T., Ma Y., Wan X., Qin A., Yao B., Zou H., Song Y., Yin D. Bnip3 mediates doxorubicin-induced cardiomyocyte pyroptosis via caspase-3/GSDME. Life Sciences. 2020;242:117186. DOI: 10.1016/j.lfs.2019.117186.

Arola O. J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki L. M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research. 2000;60(7):1789–1792.

Bartlett J. J., Trivedi P. C., Pulinilkunnil T. Autophagic dysregulation in doxorubicin cardiomyopathy. Journal of Molecular and Cellular Cardiology. 2017;104:1–8. DOI: 10.1016/j.yjmcc.2017.01.007.

Koleini N., Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8(28):46663–46680. DOI: 10.18632/oncotarget.16944.

Li M., Russo M., Pirozzi F., Tocchetti C. G., Ghigo A. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2020;1867(3):118493. DOI: 10.1016/j.bbamcr.2019.06.007.

Xiao B., Hong L., Cai X., Mei S., Zhang P., Shao L. The true colors of autophagy in doxorubicin-induced cardiotoxicity. Oncology Letters. 2019;18(3):2165–2172. DOI: 10.3892/ol.2019.10576.

Bartlett J. J., Trivedi P. C., Yeung P., Kienesberger P. C., Pulinilkunnil T. Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochemical Journal. 2016;473(21):3769–3789. DOI: 10.1042/BCJ20160385.

Li D. L., Wang Z. V., Ding G., Tan W., Luo X., Criollo A., Xie M., Jiang N., May H., Kyrychenko V., Schneider J. W., Gillette T. G., Hill J. A. Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation. 2016;133(17):1668–1687. DOI: 10.1161/CIRCULATIONAHA.115.017443.

Li M., Sala V., De Santis M. C., Cimino J., Cappello P., Pianca N., Di Bona A., Margaria J. P., Martini M., Lazzarini E., Pirozzi F., Rossi L., Franco I., Bornbaum J., Heger J., Rohrbach S., Perino A., Tocchetti C. G., Lima B. H. F., Teixeira M. M., Porporato P. E., Schulz R., Angelini A., Sandri M., Ameri P., Sciarretta S., Lima-Júnior R. C. P., Mongillo M., Zaglia T., Morello F., Novelli F., Hirsch E., Ghigo A. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation. 2018;138(7):696–711. DOI: 10.1161/CIRCULATIONAHA.117.030352.

Ejiri J., Inoue N., Kobayashi S., Shiraki R., Otsui K., Honjo T., Takahashi M., Ohashi Y., Ichikawa S., Terashima M., Mori T., Awano K., Shinke T., Shite J., Hirata K.-I., Yokozaki H., Kawashima S., Yokoyama M. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation. 2005;112(14):2114–2120. DOI: 10.1161/CIRCULATIONAHA.104.476903.

Meloni M., Caporali A., Graiani G., Lagrasta C., Katare R., Van Linthout S., Spillmann F., Campesi I., Madeddu P., Quaini F., Emanueli C. Nerve growth factor promotes cardiac repair following myocardial infarction. Circulation Research. 2010;106(7):1275–1284. DOI: 10.1161/CIRCRESAHA.109.210088.

Liao D., Zhang C., Liu N., Cao L., Wang C., Feng Q., Yao D., Long M., Jiang P. Involvement of neurotrophic signaling in doxorubicin-induced cardiotoxicity. Experimental and Therapeutic Medicine. 2020;19(2):1129–1135. DOI: 10.3892/etm.2019.8276.

Hang P., Zhao J., Sun L., Li M., Han Y., Du Z., Li Y. Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats. Journal of Cellular and Molecular Medicine. 2017;21(4):685–696. DOI: 10.1111/jcmm.13012.

Zhao J., Du J., Pan Y., Chen T., Zhao L., Zhu Y., Chen Y., Zheng Y., Liu Y., Sun L., Hang P., Du Z. Activation of cardiac TrkB receptor by its small molecular agonist 7,8-dihydroxyflavone inhibits doxorubicin-induced cardiotoxicity via enhancing mitochondrial oxidative phosphorylation. Free Radical Biology and Medicine. 2019;130:557–567. DOI: 10.1016/j.freeradbiomed.2018.11.024.

The authors declare that there are no conflicts of interest present.